文献速递前列腺癌

深度持久PSA应答与转移性激素敏感性前列腺癌结局的关联:ARASENS与ARANOTE试验启示

Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials.
PubMed 文献 · Eur Urol Oncol · 2025-04-30

本研究基于ARASENS(n=1305)和ARANOTE(n=669)两项3期试验,采用联合模型分析纵向PSA轨迹与总生存(OS)的关联。结果显示PSA下降速率每翻倍,死亡风险分别降低29%(HR 0.71,95%CI 0.69-0.74)和25%(HR 0.75,95%CI 0.72-0.78);达罗他胺治疗患者PSA轨迹更优且OS改善。

要点

  • PSA下降速率每翻倍与死亡风险显著降低相关,支持其作为预后动态指标
  • 达罗他胺治疗患者PSA下降更陡、谷值更长、上升更慢,且OS更优
  • 基线PSA更高和谷值后更陡上升与更差结局相关

核心结论

  • 联合模型显示PSA动态与OS强相关,达罗他胺可能通过改善PSA轨迹提升生存。

研究设计与样本

  • 基于ARASENS(n=1305;ADT+多西他赛±达罗他胺)和ARANOTE(n=669;ADT±达罗他胺)两项3期试验的联合模型分析。
  • 采用线性混合模型(限制性立方样条)建模PSA轨迹,Weibull模型评估OS,通过联合模型链接纵向PSA与OS。

主要发现

  • ARASENS中PSA下降速率每翻倍,死亡风险降低29%(HR 0.71,95%CI 0.69-0.74)。
  • ARANOTE中PSA下降速率每翻倍,死亡风险降低25%(HR 0.75,95%CI 0.72-0.78)。
  • 基线PSA更高和谷值后更陡上升与更差结局相关。
  • 达罗他胺治疗患者PSA下降更陡、谷值延长、上升更慢,并转化为OS改善。

临床怎么用

  • 在mHSPC治疗监测中,应关注PSA动态轨迹(如下降速率、谷值深度与持续时间),而非仅固定时间点PSA水平。
  • 达罗他胺联合方案可能通过有利的PSA轨迹改善生存,支持其作为强化治疗选择。

局限性

  • ARANOTE的OS数据为期中分析。
  • 既往治疗可能影响基线PSA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Prostate-specific antigen (PSA) is a critical biomarker in metastatic hormone-sensitive prostate cancer (mHSPC), offering insights into disease progression and treatment efficacy. An early PSA response to intensified therapy has significant prognostic implications; however, traditional methods often categorize PSA levels and focus on fixed time points, neglecting its dynamic nature. Joint models integrate longitudinal PSA trajectories and survival outcomes to provide a more comprehensive analysis. This study aims to evaluate the association between longitudinal PSA trajectories and overall survival (OS) in patients with mHSPC. METHODS: We analyzed data from two phase 3 trials: ARASENS (n = 1305; androgen deprivation therapy [ADT] + docetaxel ± darolutamide) and ARANOTE (n = 669; ADT ± darolutamide). PSA trajectories were modeled using linear mixed models with restricted cubic splines, while OS was assessed using a Weibull model. Longitudinal PSA changes and OS were linked through joint modeling. KEY FINDINGS AND LIMITATIONS: In ARASENS, each doubling of the PSA decline rate was associated with a reduction in mortality rate of 29% (hazard ratio [HR] 0.71, 95% confidence interval [CI]: 0.69, 0.74); in ARANOTE, the reduction was 25% (HR 0.75, 95% CI: 0.72, 0.78). Higher baseline PSA levels and sharper postnadir increases were linked to worse outcomes. Darolutamide-treated patients showed favorable PSA trajectories, marked by steeper declines, prolonged nadirs, and slower increases, translating into improved OS. Limitations include interim OS data in ARANOTE and influence of prior treatments on baseline PSA. CONCLUSIONS AND CLINICAL IMPLICATIONS: Joint modeling demonstrates a strong association between PSA dynamics and OS, underscoring darolutamide's potential to positively influence PSA trajectories and improve survival in mHSPC.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Wallis CJD, Ekberg S, Morgans AK, et al. Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials. Eur Urol Oncol. 2025. PMID: 40312181. doi:10.1016/j.euo.2025.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。